What's Happening?
The Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial, which evaluates the Spur® Peripheral Retrievable Scaffold System for treating chronic limb-threatening ischemia (CLTI). The study, supported by Reflow
Medical, Inc., aims to understand early vessel recoil following below-the-knee treatment. It will include up to 40 patients, focusing on those with diabetes and end-stage renal disease, ensuring balanced female representation.
Why It's Important?
This trial addresses a critical gap in CLTI research by focusing on underrepresented patient groups, such as those with diabetes and end-stage renal disease. The study's findings could lead to improved treatment strategies and outcomes for these high-risk populations. Additionally, the emphasis on female representation in the trial could provide more comprehensive data, influencing future medical research and treatment protocols.
What's Next?
The trial will monitor patients for early vessel recoil and other outcomes over 12 months. The results could inform future clinical practices and potentially lead to broader adoption of the Spur® system in treating complex peripheral artery disease.















